Recap: Supernus Pharmaceuticals Q4 Earnings
Portfolio Pulse from Benzinga Insights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 earnings with an EPS of $0.39, missing estimates by -29% and a revenue decrease of $3.01 million from the previous year. Despite missing last quarter's EPS estimate, the share price increased by 11% the following day. The company's past earnings performance shows mixed results with both misses and beats on EPS and revenue estimates.
February 27, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Supernus Pharmaceuticals reported a significant miss in Q4 earnings with a -29% deviation from the estimated EPS and a year-over-year revenue decrease. Despite a similar miss last quarter, the stock price increased by 11% the following day.
The significant miss in earnings and revenue decrease could typically lead to a negative short-term impact on SUPN's stock price. However, considering the stock's previous reaction to a similar earnings miss with an 11% increase, the short-term impact is uncertain. This suggests that market sentiment and other factors may play a more significant role in the stock's immediate price movement.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100